Calla Lily Clinical Care
Calla Lily Clinical Care develops patented medical device technologies engineered to improve intravaginal drug delivery for women's health, focusing on clinical needs such as fertility support, pregnancy management, prevention of recurrent miscarriage, and restoration of the vaginal microbiome. Recognized for innovation, the company maintains collaborative partnerships with clinical and academic institutions and secures funding to advance clinical trials and R&D. Their technology is designed for leak prevention, convenience, and dosing confidence, with a strong commitment to sustainability and social impact as a certified B-Corporation.
Calla Lily Clinical Care
Charles House 108-110 Finchley Road London NW3 5JJ UK
Calla Lily Clinical Care is currently seeking investment
Calla Lily Clinical Care is seeking a seed investment in the range of 1m-5m
What We Do
A patented and FDA-cleared platform for intravaginal delivery of medicines and hormones, utilizing a biocompatible scaffold, mini-liner, and flexible sheath to prevent leakage, enable precise dosage, and facilitate mess-free insertion and removal.
Device under development for effective, non-invasive collection of biological samples to support biomarker-based diagnostic tests for gynecological conditions.
Collaboration with academic, NHS, and pharmaceutical partners to design and execute clinical trials evaluating drug delivery devices and platforms in reproductive health.
Development of funding strategies, grant writing, and management of relationships with funding agencies for medical device innovations.
Digital Health Technologies
Routes of Administration
FDA Regulated Medical Devices
Infectious Diseases
Application Area
Key People
Co-founder & Chairman
Co-founder & CEO
Principal Scientist
Product Development Manager
R&D Manager
Chief Product Officer
News & Updates
Secured NIHR funding for first clinical trial of the drug delivery technology in miscarriage prevention.
Certified as a B-Corp for meeting high social and environmental standards.
Obtained US FDA clearance and secured multiple patents across jurisdictions for platform technology.
Recertified to ISO9001 and began the process towards ISO13485 certification for quality management.
Recognized as one of the best startups at MedFemTech Congress in Paris.
Recognition of the Global Access Fellowship Program partnership, providing drug development experience to PharmD students for advancing healthcare access.
Case study highlighting the transformation of vaginal drug delivery and the company's success in grant funding and private investment.
BBC News coverage on the novel leak-free vaginal drug delivery device and its impact on miscarriage treatment.
Interview with Professor Siobhan Quenby about the clinical trial of a progesterone-loaded vaginal drug delivery device.
NIHR announces funding of a first-of-its-kind trial to assess a novel device for treating threatened miscarriage.
Coverage on clinical trial leadership by UHCW NHS Trust to test a new device for threatened miscarriage.
Article outlining the development of a next-generation vaginal drug delivery platform and its clinical implications.
Feature article with Dr Lara Zibners, discussing the challenges and innovations in advancing women's health.
Recognition as a 2025 finalist in the HLTH Europe Startup Pitch competition.
Showcasing the company’s commitment to balancing people, planet, and profit through social and environmental impact.
Personal account of innovation in diagnostic sample collection for endometriosis and related conditions.
Participation in the American Society for Reproductive Medicine Scientific Congress & Expo 2025, showcasing vaginal drug delivery innovation.
Co-founder Dr Lara Zibners participated on the main stage panel at HLTH Vegas, discussing innovation and education in hormone replacement therapy.
Presentation at Women's Health Week conference regarding the development and future impact of the drug delivery platform for women.
Participation in the inaugural Women's Health Horizons (WHH) event, engaging in panels and keynotes on advancing women's health innovation.
Appointment of Dr. Lara Zibners to the Strategic Advisory Board for Women’s Health Horizons (WHH), contributing to women's health strategy.
Attendance at the largest European women's health conference of the year, highlighting the impact of the drug delivery platform in care transformation.
Participation in the Milken Institute Asia Summit 2025, focusing on healthcare innovation and regional trends.
Dr. Lara Zibners featured as a key speaker discussing women's health innovation at the Society of Physician Entrepreneurs event in Boston.
Panel participation by Dr. Lara Zibners on pregnancy loss, exploring advancements and the future in women's health care.
Presentation at the 34th Singapore Pharmacy Congress on user-centric vaginal drug delivery platform and its role in improving patient care.
Engagement with a major health and hygiene company at their Munich office to discuss innovation integration in healthcare.
Presentation at LSI Europe 2025 conference focusing on medtech and healthtech innovation.
Participation in the Innovate UK & Texas Medical Center Innovation Factory accelerator, supporting healthtech startups.
Speaker presentation on translational strategy and patient-centric vaginal drug delivery platforms at the Singapore Pharmacy Congress.
Participation in the first Women’s Research Day at Ohio State University, fostering interdisciplinary collaborations to advance women's health.
Hosting cohort days for Zinc Innovation Fellows, providing practical innovation training in women's health ventures.
Panel participation at Innovate Local on experiences expanding into international markets with Innovate UK Global Business Innovation Programmes.
Collaboration with Massachusetts Institute of Technology on innovation and engineering in women's health technology.
Summer Shareholder Reception event at company headquarters for stakeholders to visit facilities and meet the growing team.
Participation in ESHRE Congress 2025, engaging with international reproductive medicine leaders and presenting innovations.
Attendance at the 41st Annual ESHRE Congress in Paris, fostering discussions on reproductive health.